The BSH Guidelines Official Podcast

Dr Tracey Chan and Dr Dima El-Sharkawi discuss the Updated guidelines for the diagnosis and management of tumour lysis syndrome in adults and children, published in 2025.

Dr Matthew Wilson, Dr Sridhar Chaganti and Dr Wendy Osborne discuss the Clinical management of bispecific antibody therapy for lymphoma Good Practice Paper, published in 2025. 

Dr Eyre is a consultant haematologist specialising in lymphoid malignancies in Oxford. 

He has completed an MD Doctorate Thesis in 2017.  He is an investigator on several national lymphoid trials and has published over 170 peer-review articles on lymphoma and CLL.  He is the chair of the low-grade lymphoma clinical trial research group and a core member several lymphoma study groups.  He is a member of the BSH guideline writing groups for various lymphoma subtypes and the lead author for the new ESMO Lymphoma guidelines.  ​He is also an Associate Editor at the British Journal of Haematology.

Podcast recording by James Griffin on the Guideline: Apheresis procedures for the treatment of patients and for the collection of cellular therapy products.

Dr Deepa J. Arachchillage and Dr Jenny Tam present a review of the Guidelines on the investigation and management of antiphospholipid syndrome. Published: 04 August 2025

Dr Matthew Wilson and Dr Kate Cwynarski discuss the Central nervous system prophylaxis in large B-cell lymphoma Good Practice Paper, published in 2024.

Professor Christopher Fox, Dr Sridhar Chaganti and Dr Bernard Maybury discuss the Management of relapsed or refractory large B-cell lymphoma Guideline, published in 2025.

This podcast is the first of a series of three recordings of the Lymphoma Special Interest Group (SIG) Education Session at the 2025 BSH Annual Scientific Meeting.  The Lymphoma SIG is delighted to share talks from three great speakers with the wider audience.

In this recording, Dr David Lewis discusses first-line treatment for mantle cell lymphoma in 2025, focusing on three main themes: 1) the emerging use of Bruton’s tyrosine kinase inhibitors (BTKis) in first-line treatment, 2) the role of autologous stem cell transplant, and 3) the clinical utility of minimal residual disease (MRD).

Dr David Lewis is a Consultant Haematologist at the University Hospitals Plymouth and an Honorary Associate Professor at the University of Plymouth.  He is the Chief Investigator of the ENRICH trial – a randomised, open-label study of Rituximab/Ibrutinib versus. Rituximab/Chemotherapy in older patients with untreated mantle cell lymphoma.

Dr Cathy Burton chaired the “Top Abstracts in Lymphoma” session at BSH 2025.  In this episode, she shares with us the highlights from this session.

Dr Burton is a Consultant Haematologist at St James’s University Hospital, Leeds, specializing in Lymphoma and Diagnostics. She is heavily engaged in translational research in lymphoma and is Chair of the Hodgkin lymphoma study group, Deputy Chair of the Lymphoma Science study group and a member of the UK Lymphoma Research Group. She has recently been involved in writing the diffuse large B cell lymphoma guidelines and is the chair of the BSH Lymphoma Special Interest Group.